Paul Hesketh to Administration, Oral
This is a "connection" page, showing publications Paul Hesketh has written about Administration, Oral.
Connection Strength
0.322
-
Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014 Jul; 25(7):1340-1346.
Score: 0.098
-
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003 Nov 15; 21(22):4112-9.
Score: 0.048
-
Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J. 2000 May-Jun; 6(3):157-61.
Score: 0.038
-
Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan; 8(1):46-8.
Score: 0.037
-
Hesketh P. Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Semin Oncol. 1995 Aug; 22(4 Suppl 10):19-23.
Score: 0.027
-
Hesketh PJ. Oral ondansetron: a useful addition to the supportive care armamentarium? Am J Clin Oncol. 1994 Apr; 17(2):147-9.
Score: 0.025
-
Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003 May 01; 97(9):2290-300.
Score: 0.012
-
Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73.
Score: 0.008
-
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998 Feb; 16(2):754-60.
Score: 0.008
-
Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer. 1997 Mar 15; 79(6):1216-24.
Score: 0.008
-
Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, Reeves JA, Porter LL, Benedict CR, Hahne WF. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am. 1997 Jan-Feb; 3(1):45-51.
Score: 0.007
-
Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am. 1996 Mar-Apr; 2(2):85-90.
Score: 0.007